Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (56)

« Back to Publications

Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: An economic evaluation based on data from the LENS trial.

Scotland G. et al, (2025), Diabet Med, 42

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.

EMPA-KIDNEY Collaborative Group . et al, (2025), N Engl J Med, 392, 777 - 787

Long-term follow-up of treatment comparisons in RECOVERY: a randomised, open-label, platform trial for patients hospitalised with COVID-19

Horby P. et al, (2025)

Design, recruitment and baseline characteristics of the LENS trial.

LENS Collaborative Group ., (2024), Diabet Med, 41

Effect of Fenofibrate on Progression of Diabetic Retinopathy.

Preiss D. et al, (2024), NEJM Evid, 3

ASCEND-Eye: Effects of Aspirin on Diabetic Retinopathy.

Sammons EL. et al, (2024), Ophthalmology, 131, 771 - 779

Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England.

Pessoa-Amorim G. et al, (2024), Trials, 25

ASCEND-Eye: Effects of Omega-3 Fatty Acids on Diabetic Retinopathy.

Sammons EL. et al, (2024), Ophthalmology, 131, 526 - 533

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group ., (2024), Lancet Child Adolesc Health, 8, 190 - 200

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.

EMPA-KIDNEY Collaborative Group ., (2024), Lancet Diabetes Endocrinol, 12, 51 - 60

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.

EMPA-KIDNEY Collaborative Group ., (2024), Lancet Diabetes Endocrinol, 12, 39 - 50

SCEND-Eye: Rationale, design and baseline characteristics for a sub-study of the ASCEND randomised trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration.

Sammons E. et al, (2023), Contemp Clin Trials Commun, 35

Reliability of major bleeding events in UK routine data versus clinical trial adjudicated follow-up data.

Harper C. et al, (2023), Heart, 109, 1467 - 1472

Empagliflozin in Patients with Chronic Kidney Disease.

The EMPA-KIDNEY Collaborative Group . et al, (2023), N Engl J Med, 388, 117 - 127

Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy.

Cholesterol Treatment Trialists' Collaboration ., (2022), Clin Trials, 19, 593 - 604

Load More